share_log

Laidlaw & Co. Initiates Coverage On Evofem Biosciences with Buy Rating, Announces Price Target of $3.5

Laidlaw & Co. Initiates Coverage On Evofem Biosciences with Buy Rating, Announces Price Target of $3.5

Laidlaw & Co.以買入評級啓動對Evofem Biosciences的報道,宣佈目標股價爲3.5美元
Benzinga Real-time News ·  2022/06/02 09:30

Laidlaw & Co. analyst Yale Jen initiates coverage on Evofem Biosciences (NASDAQ:EVFM) with a Buy rating and announces Price Target of $3.5.

Laidlaw & Co. 分析師耶魯·詹開始對Evofem Biosciences(納斯達克股票代碼:EVFM)進行報道,評級爲買入,並宣佈目標股價爲3.5美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論